Codexis, Inc. Competitors

Novozymes has combined with Chr. Hansen to become Novonesis: linkedin.com/company/novonesis. This global biosolutions company of 10,000 people is transforming how the world produces, consumes and lives. In 30-plus industries, its biosolutions help businesses meet their needs and the needs of our planet. Novozymes was formed in 2000 when Novo Nordisk split into three companies: Novo Nordisk A/S, Novozymes A/S and Novo A/S. Novozymes was the world leader in biological solutions with a commitment to Rethink Tomorrow. It served 130 markets with enzymatic, microbial and advanced protein solutions. The company’s solutions enabled higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits. In December 2022, Novozymes and Chr. Hansen entered into an agreement to create a leading global biosolutions partner by combining the two companies. The goal was to unleash the full potential of biosolutions and generate significant value for all stakeholders and society. The combination was completed on January 29, 2024 and Novonesis was born. The name means ‘a new beginning’ and is derived from the Greek word ‘genesis’. It reflects a new era where we’ll better our world with biology. You can find Novonesis on LinkedIn here: linkedin.com/company/novonesis. Novozymes A/S, part of Novonesis Group.

Amyris is a vertically integrated biomanufacturing company that creates specialty molecules for a range of industries, including flavors and fragrances, advanced materials, beauty and personal care, food, and more. Using advanced fermentation technology, Amyris customizes, creates, and manufactures ingredients that enhance lives, protect ecosystems, and take products to the next level of performance. Amyris was founded in 2003 with a bold humanitarian vision to transform access to a lifesaving antimalarial compound using biotechnology. Now, with over two decades of proven commercial success, our proprietary platform is redefining the precision, consistency, and sustainability that is possible with renewable biological chemistry.

Ion Torrent has developed a DNA sequencing system that directly translates chemical signals (A, C, G, T) into digital information (0, 1) on a semiconductor chip. The result is a sequencing system that is simpler, faster, more cost effective and scalable than any other technology available. Because Ion Torrent produces its proprietary semiconductor chips in standard CMOS factories, we leverage the $1 trillion dollar investment that has been made in the semiconductor industry over the past 40 years. This enables us to directly benefit from four decades of exponential improvement in semiconductor technology, usually expressed as Moore’s Law. The company was founded in August 2007 by Jonathan Rothberg, a pioneer of high-speed, massively parallel DNA sequencing. Ion Torrent is based in Guilford, Connecticut with offices in San Francisco. Ion Torrent will launch the Ion Personal Genome Machine sequencer in 2010. For more information about Ion Torrent, visit www.lifetechnologies.com/iontorrent